Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors inside the central anxious procedure, conolidine modulates alternate molecular targets. A Science Improvements study located that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://vernonw219bef2.frewwebs.com/profile